INCB treatment inhibited % colony growth of several AML (OCI-AML5, THP1 and OCI-AML2) and post-MPN sAML cell types (SET-2 and HEL92.1.7) (Fig. 3E, F), as well as increased % of AML cells expressing CD11b and CD86 (Fig. 3G, H). The gene discussed is RUNX3; the disease is myeloproliferative disorder.